Biostax Corp. Asset Impairment Charges
Biostax Corp. reported Asset Impairment Charges of $2.65 million for the 12-month period ending 2022-12-31, per its 10-K/A filed 2024-07-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2024-07-05
- Biostax Corp. asset impairment charges for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Biostax Corp. asset impairment charges for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Biostax Corp. asset impairment charges for the quarter ending 2022-06-30 was $362.25K.
- Biostax Corp. asset impairment charges for the quarter ending 2022-03-31 was $2.28M.
- Biostax Corp. asset impairment charges for fiscal 2022 was $2.65M, a 15.13% decline from fiscal 2021.
- Biostax Corp. asset impairment charges for fiscal 2021 was $3.12M.
| Period end | Asset Impairment Charges 3 month | Asset Impairment Charges 6 month | Asset Impairment Charges 9 month | Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-07-05 | $0.00 derived: sum of 2 quarters · filed 2024-07-05 | $362.25K derived: sum of 3 quarters · filed 2024-07-05 | $2.65M 10-K/A · filed 2024-07-05 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $362.25K derived: sum of 2 quarters · filed 2023-11-14 | $2.65M 10-Q · filed 2023-11-14 | $2.66M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $362.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18 | $2.65M 10-Q · filed 2023-08-18 | $2.66M derived: sum of 3 quarters · filed 2023-08-18 | $5.76M derived: sum of 4 quarters · filed 2023-08-18 |
| 2022-03-31 | $2.28M 10-Q · filed 2023-05-12 | $2.29M derived: sum of 2 quarters · filed 2023-05-12 | $5.40M derived: sum of 3 quarters · filed 2023-05-12 | |
| 2021-12-31 | $11.50K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-10 | $3.12M derived: sum of 2 quarters · filed 2023-04-10 | $3.12M 10-K · filed 2023-04-10 | |
| 2021-09-30 | $3.10M 10-Q · filed 2022-11-14 | $3.10M 10-Q · filed 2022-11-14 |